Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002096075-25-000001
Filing Date
2025-11-10
Accepted
2025-11-10 18:03:03
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8037
2 jfa.pdf EX-99 111483
  Complete submission text file 0002096075-25-000001.txt   163717
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Subject) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-50777 | Film No.: 251467678
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 528 W. 4TH AVE NORTH POLE AK 99705
Business Address 528 W. 4TH AVE NORTH POLE AK 99705 9073710464
Jeffrey Matthew Gryga Irrevocable Trust (Filed by) CIK: 0002096075 (see all company filings)

EIN.: 416578444 | State of Incorp.: AK | Fiscal Year End: 1231
Type: SCHEDULE 13G